Ensuring Canada remains an attractive destination for pharmaceutical innovation.
The Patented Medicine Prices Review Board (PMPRB) ensures patented medicines sold in Canada are not excessively priced. IMC has highlighted how changes to the PMPRB affect patient access to medicines and Canada’s attractiveness for future pharmaceutical innovation.
A recent report by the Patented Medicine Prices Review Board shows increased growth for private drug plan costs but promising pharmaceutical innovation, says Joe Farago, executive director of private payers and investment at Innovative Medicines Canada.
Ottawa, June 6, 2023 – Recently released Statistics Canada data demonstrates the economic impact of the innovative research and development […]
Ottawa, ON – Innovative Medicines Canada (IMC) welcomes the new leadership of the Patented Medicine Prices Review Board (PMPRB) with […]
IMC’s members continue to have significant concerns regarding changes to the PMPRB and future Guidelines that will implement the revised schedule of international reference countries.
IMC opposes a January 15, 2021 proposal to redefine ‘gap’ medicines and change the timeline for compliance – which halves the transition period to six months.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
Breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
Our member companies, which range from early-stage startups to established organizations, are revolutionizing healthcare through the discovery and development of new […]
Informative content to keep you up to date on the most pressing issues facing our industry.
